E-LIB Suche - Ergebnisse für: Moskowitz, A. J.

1

PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblas..:

Moskowitz, A. ; Savage, K. ; Feldman, T....
Hematological Oncology. 41 (2023) S2 - p. 351-353 , 2023

Link: https://doi.org/10.1002/..

2

Feasibility of Passive ECG Bio-sensing and EMA Emotion Repo..:

Cummings, P. ; Petitclerc, A. ; Moskowitz, J....
Affective Science. 3 (2022) 4 - p. 849-861 , 2022

Link: https://doi.org/10.1007/..

3

PREDICTIVE VALUE OF QUANTITATIVE 18F‐FDG‐PET‐CT RADIOMICS A..:

Driessen, J ; Zwezerijnen, G. J. C ; Schöder, H...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

4

A PHASE II TRIAL OF REDUCED DOSE BRENTUXIMAB VEDOTIN FOR CU..:

Khan, N. ; Noor, S. ; Geller, S....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

5

THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ..:

Horwitz, S. M. ; Moskowitz, A. J. ; Mehta‐Shah, N....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

6

NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY ..:

Zinzani, P. L. ; Santoro, A. ; Gritti, G....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

7

CLINICAL OUTCOMES AND THE ROLE OF OBSERVATION IN EARLY‐STAG..:

Sha, F. ; Okwali, M. ; Alperovich, A....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

8

CLINICAL CHARACTERISTICS AND OUTCOMES OF ADULT LYMPHOMA‐ASS..:

Lee, C. Y ; Wills Sanin, B ; Vardhana, S. A.
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

9

1172 Sleep Education Improves Screening for Sleep Disorders..:

Parathasarathy, s ; Combs, D ; Moskowitz, A..
Sleep. 43 (2020) Supplement_1 - p. A447-A448 , 2020

Link: https://doi.org/10.1093/..

10

High Local Control And Overall Survival With Radiotherapy F..:

Wijetunga, N.A.A. ; Lee, J. ; Imber, B.S....
International Journal of Radiation Oncology*Biology*Physics. 108 (2020) 3 - p. e759 , 2020

Link: https://doi.org/10.1016/..

11

NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/RE..:

Zinzani, P.L. ; Santoro, A. ; Gritti, G....
Hematological Oncology. 37 (2019) S2 - p. 157-158 , 2019

Link: https://doi.org/10.1002/..

12

CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LA..:

Bobillo, S. ; Joffe, E. ; Lavery, J....
Hematological Oncology. 37 (2019) S2 - p. 251-252 , 2019

Link: https://doi.org/10.1002/..

13

TREATMENT AND OUTCOMES OF PATIENTS WITH NK/T‐CELL LYMPHOMA ..:

Ghione, P. ; Qi, S. ; Imber, B.S....
Hematological Oncology. 37 (2019) S2 - p. 477-478 , 2019

Link: https://doi.org/10.1002/..

14

INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORM..:

Rajeeve, S. ; Bobillo, S.V. ; Zelenetz, A.D....
Hematological Oncology. 37 (2019) S2 - p. 264-266 , 2019

Link: https://doi.org/10.1002/..

15

MULTI‐CENTER PHASE II STUDY OF ORAL AZACITIDINE (CC‐486) PL..:

Ruan, J. ; Leonard, J.P. ; Coleman, M....
Hematological Oncology. 37 (2019) S2 - p. 560-561 , 2019

Link: https://doi.org/10.1002/..